Johnson Nancy JoAnn sold $1.8M of BLLN

Johnson Nancy JoAnn (See Remarks) sold 14,199 shares of BillionToOne, Inc. (BLLN) at an average of $128.29 ($126.98–$129.78, $1.82M total) across 4 trades on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Johnson Nancy JoAnn
Published Jul 20, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

02

Market read

Traders may treat this as routine insider activity with limited fundamental implications, but it can be used to monitor insider selling trends.

03

What to watch

The net holdings after the sale are 6,900 shares, but the article provides no context on prior sale cadence or total insider ownership changes beyond this transaction.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-07-20, covering sales executed on 2026-07-16.

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

Form 4 shows officer Johnson Nancy JoAnn sold 14,199 shares of BillionToOne at about $128.29 weighted average under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more about sentiment than new company information.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it does not disclose new operating, regulatory, or financial results.

Market effects

No sector read-through; this is company-specific insider selling with no new guidance or regulatory development.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with internal views on valuation or liquidity needs, so traders may still watch for follow-on selling patterns.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider transaction disclosure (BLLN).

  • Johnson Nancy JoAnn

    Officer who sold 14,199 shares across four trades on 2026-07-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.